MRKMerck Sharp & Dohme LLCRunning, no new patients
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
Bladder Cancer
12Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Oct 2025, none posted yet
Counts until it's fixed
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score12
Score over time
- Stage
- Phase 3
- Patients
- 808 (final count)
- Started
- Apr 21, 2021
- Main results expected
- Oct 27, 2025
- Fully finished
- May 18, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Event-Free Survival (EFS)
Measured over: Up to ~68 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2025-10-27, no fading
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04700124 · record last updated 2026-07-16 · checked 2026-11-09 15:47 UTC